company background image

Novo Nordisk NYSE:NVO Stock Report

Last Price


Market Cap







17 Aug, 2022


Company Financials +
NVO fundamental analysis
Snowflake Score
Future Growth3/6
Past Performance5/6
Financial Health4/6

NVO Stock Overview

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide.

Novo Nordisk A/S Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Novo Nordisk
Historical stock prices
Current Share Pricekr.104.81
52 Week Highkr.122.16
52 Week Lowkr.91.51
1 Month Change-7.23%
3 Month Change0.73%
1 Year Change0.77%
3 Year Change102.26%
5 Year Change131.01%
Change since IPO20,967.38%

Recent News & Updates

Aug 11

Novo Nordisk goes ex-dividend tomorrow

Novo Nordisk (NVO) declared $0.411/share dividend. Payable Aug. 23; for shareholders of record Aug. 15; ex-div Aug. 12. See NVO Dividend Scorecard, Yield Chart, & Dividend Growth.

Jul 11

Novo Nordisk achieves positive data with two hemophilia candidates

Two Novo Nordisk (NVO) candidates for hemophilia garnered positive results, one in a phase 3 study and the other in a phase 1/2 trial. Phase 3 results on concizumab for hemophilia A or B showed the anti-tissue factor pathway inhibitor (TFPI) antibody along with inhibitors led to an 86% reduction in treated spontaneous and traumatic bleeds, with an estimated mean annual bleeding rate of 1.7 compared to 11.8 without concizumab. Novo Nordisk (NVO) said it plans on regulatory filings for concizumab in the second half of this in the US and Japan, and in 2023 in the EU and the UK. Separately, there were no thromboembolic events or serious adverse events reported in a phase 1/2 trial of next-generation Factor VIIIa (FVIIIa) mimetic Mim8. Novo Nordisk (NVO) said dosing in the phase 3 trial should begin in Q4. Seeking Alpha's Quant Rating views Novo Nordisk as a hold with high grades for profitability, revisions, and momentum.

Shareholder Returns

NVOUS PharmaceuticalsUS Market

Return vs Industry: NVO exceeded the US Pharmaceuticals industry which returned -0.9% over the past year.

Return vs Market: NVO exceeded the US Market which returned -8.9% over the past year.

Price Volatility

Is NVO's price volatile compared to industry and market?
NVO volatility
NVO Average Weekly Movement5.4%
Pharmaceuticals Industry Average Movement12.1%
Market Average Movement7.6%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: NVO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: NVO's weekly volatility (5%) has been stable over the past year.

About the Company

192350,816Lars Jorgensen

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.

Novo Nordisk A/S Fundamentals Summary

How do Novo Nordisk's earnings and revenue compare to its market cap?
NVO fundamental statistics
Market CapUS$239.45b
Earnings (TTM)US$6.91b
Revenue (TTM)US$21.50b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NVO income statement (TTM)
Cost of Revenuekr.25.29b
Gross Profitkr.131.97b
Other Expenseskr.81.43b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 02, 2022

Earnings per share (EPS)22.30
Gross Margin83.92%
Net Profit Margin32.14%
Debt/Equity Ratio34.2%

How did NVO perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio